Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J H Lipton

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
Bone Marrow Transplantation|May 1, 1997
Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplantsF Z Al-Fiar, R Colwill, J H Lipton, et al.
Hematology (Amsterdam, Netherlands)|May 15, 2003
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemiasV Gupta, S Kamel-Reid, M D Minden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantationT L Kiss, M Abdolell, N Jamal, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|September 11, 2002
Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantationT K Marras, K Sanders, J H Lipton, et al.
Bone Marrow Transplantation|October 31, 2002
Pulmonary function abnormalities after allogeneic marrow transplantation: a systematic review and assessment of an existing predictive instrumentT K Marras, J P Szalai, C K Chan, et al.
Bone Marrow Transplantation|January 13, 2004
Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantationT K Marras, C K Chan, J H Lipton, et al.
Bone Marrow Transplantation|March 7, 2003
Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphomaT L Kiss, T Panzarella, H A Messner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapyD H Kim, W Xu, S Kamel-Reid, et al.
Current Oncology (Toronto, Ont.)|July 14, 2012
Recommendations of the canadian consensus group on the management of chronic myeloid leukemiaP Laneuville, M J Barnett, R Bélanger, et al.
Bone Marrow Transplantation|February 12, 2013
Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCTD Kim, G Al-Dawsari, H Chang, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Bone Marrow Transplantation|May 1, 1997
Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplantsF Z Al-Fiar, R Colwill, J H Lipton, et al.
Hematology (Amsterdam, Netherlands)|May 15, 2003
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemiasV Gupta, S Kamel-Reid, M D Minden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantationT L Kiss, M Abdolell, N Jamal, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|September 11, 2002
Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantationT K Marras, K Sanders, J H Lipton, et al.
Bone Marrow Transplantation|October 31, 2002
Pulmonary function abnormalities after allogeneic marrow transplantation: a systematic review and assessment of an existing predictive instrumentT K Marras, J P Szalai, C K Chan, et al.
Bone Marrow Transplantation|January 13, 2004
Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantationT K Marras, C K Chan, J H Lipton, et al.
Bone Marrow Transplantation|March 7, 2003
Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphomaT L Kiss, T Panzarella, H A Messner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapyD H Kim, W Xu, S Kamel-Reid, et al.
Current Oncology (Toronto, Ont.)|July 14, 2012
Recommendations of the canadian consensus group on the management of chronic myeloid leukemiaP Laneuville, M J Barnett, R Bélanger, et al.
Bone Marrow Transplantation|February 12, 2013
Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCTD Kim, G Al-Dawsari, H Chang, et al.
Pageof 11